Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, safety and HRQoL of cytisine in smoking cessation
TCTR20180312001Phase 2Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- May 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytisinicline in nicotine dependence, sponsored by Government Pharmaceutical Organization. Planned start May 2018; status: not yet recruiting.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on TCTR20180312001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180312001.